Who founded Pulmocide?

Pulmocide was founded by Pete Strong, Garth Rapeport, Kazuhiro Ito, John Murray in 2013.

Who are Pulmocide's investors?

Pulmocide's investors include Adjuvant Capital, Asahi Kasei Corporate Venture Capital, Dementia Discovery Fund, F-Prime Capital, Jeito Capital, Longwood Fund, SR One Capital Management, SV Health Investors and 3 more.

How much funding has Pulmocide raised?

Pulmocide has disclosed $82M raised across 2 of its 4 known rounds.

Pulmocide

Founded 2013 · 18 employees on LinkedIn · 18 known investors

Find your way into Pulmocide

123 people in our graph share verified history with the Pulmocide team — schools, employers, funds. One of them is your warm intro.

Anna Marie Pyleunlockedknows Kazuhiro Ito · together at Rigimmune (overlapped)

knows the team · via Rigimmune

knows the team · via Institute of Science Tokyo (Science Tokyo)

×3knows the team · via Hokkaido University

knows the team · via Imperial College London

×4knows the team · via Pulmocide

Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis. Its lead investigational drug, opelconazole, is an inhaled antifungal agent in Phase 3 trials for patients with invasive pulmonary aspergillosis not responding to standard care.

Biotech Healthtech

Founders & leadership

Pulmocide was founded in 2013 by Pete Strong, Garth Rapeport, Kazuhiro Ito, and John Murray.

Pete StrongCo-founder

Garth RapeportCo-founder

Kazuhiro Ito Co-founderKazuhiro Ito spent 13 years at Sankyo Pharmaceutical leading the allergy disease section, followed by 15 years at the National Heart and Lung Institute at Imperial College focusing on respiratory inflammation and infection research. He co-founded RespiVert Ltd in 2007 (acquired by Janssen in 2010) and Pulmocide in 2013, where he leads discovery and clinical development of inhaled anti-infective therapies.

John MurrayCo-founder

David MantusFounder

Investors · 18

Adjuvant Capitallisted by Adjuvant CapitalNew York · $10M – $25M

How we know: Adjuvant Capital's portfolio page · a partner's Signal profile · globenewswire.com · Not right? Tell us

Asahi Kasei Corporate Venture Capitallisted by Asahi Kasei Corporate Venture CapitalMenlo Park · $200K – $5M

How we know: Asahi Kasei Corporate Venture Capital's portfolio page · Not right? Tell us

Dementia Discovery Fundlisted by Dementia Discovery FundLondon

How we know: Dementia Discovery Fund's portfolio page · Not right? Tell us

F-Prime Capitallisted by F-Prime CapitalCambridge · $3M – $10M

How we know: F-Prime Capital's portfolio page · globenewswire.com · Not right? Tell us

Jeito Capitallisted by Jeito CapitalParis

How we know: globenewswire.com · Not right? Tell us

Longwood Fundlisted by Longwood FundBoston

How we know: Longwood Fund's portfolio page · globenewswire.com · the VCSheet dataset · Not right? Tell us

SR One Capital Managementlisted by SR One Capital ManagementRedwood City

How we know: SR One Capital Management's portfolio page · Not right? Tell us

SV Health Investorslisted by SV Health InvestorsLondon · $1M – $20M

How we know: SV Health Investors's portfolio page · globenewswire.com · Not right? Tell us

Vivo Capitallisted by Vivo CapitalPalo Alto · $10M – $50M

How we know: Vivo Capital's portfolio page · pulmocide.com · Not right? Tell us

Johnson & Johnson Innovation – JJDCreportedNew Brunswick

How we know: globenewswire.com · Not right? Tell us

SV Life SciencesreportedBoston

How we know: funding news · uktech.news · Not right? Tell us

Also in the syndicate · 7

Asahi Kasei PharmaCystic Fibrosis FoundationIP Group plcJohnson & JohnsonPictet Alternative AdvisorsleadSR OneTouchstone Innovations

Funding

SEC filings, press & company announcements

$82M disclosed across 2 of 4 rounds · 2017–2022

$52MSeries C extension roundDec 2022 · 2 sources
Pictet Alternative Advisors (lead), Vivo Capital (lead), Adjuvant Capital, Asahi Kasei Pharma, Cystic Fibrosis Foundation, F-Prime Capital, IP Group plc, Jeito Capital, Johnson & Johnson Innovation – JJDC, Inc., Longwood Fund, SR One, SV Health Investors
Source ↗
Undisclosed amountSeries CMay 2021
Jeito Capital (lead), Adjuvant Capital, Asahi Kasei Pharma, F-Prime Capital, IP Group plc, Johnson & Johnson Innovation – JJDC, Inc., Longwood Fund, SR One, SV Health Investors
Source ↗
$30MSeries BMar 2017 · 2 sources
F-prime, Johnson & Johnson, SV Life Sciences, Touchstone Innovations
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Pulmocide Raises $52 Million to Fund Additional Late-Stage Development of Opelconazole | Pulmocidepulmocide.com · Dec 2022

Frequently asked questions

What does Pulmocide do?: Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis. Its lead investigational drug, opelconazole, is an inhaled antifungal agent in Phase 3 trials for patients with invasive pulmonary aspergillosis not responding to standard care.
Who founded Pulmocide?: Pulmocide was founded by Pete Strong, Garth Rapeport, Kazuhiro Ito, John Murray in 2013.
Who are Pulmocide's investors?: Pulmocide's investors include Adjuvant Capital, Asahi Kasei Corporate Venture Capital, Dementia Discovery Fund, F-Prime Capital, Jeito Capital, Longwood Fund, SR One Capital Management, SV Health Investors and 3 more.
How much funding has Pulmocide raised?: Pulmocide has disclosed $82M raised across 2 of its 4 known rounds.